GlassScriptPhysician profile
Richard R Recko
NPI 1356365761
$4,008.30
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $27.59 · 2021: $3,486 · 2022: $284 · 2023: $63.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $3,280.62 | 2021 | |
| Smith+Nephew, INC. | $170.48 | 2019-2023 | Regranex, Collagenase Santyl |
| Organogenesis INC. | $127.36 | 2021 | |
| Aroa Biosurgery Incorporated | $97.78 | 2019 | |
| Paratek Pharmaceuticals, INC. | $92.63 | 2022 | |
| Horizon Therapeutics Plc | $81.19 | 2022 | |
| Nabriva Therapeutics, Plc | $32.95 | 2021 | |
| Ovik Health, LLC | $27.59 | 2020 | |
| Integra Lifesciences Corporation | $18.05 | 2019 | |
| Kci USA, INC. | $16.29 | 2019 | |
| Melinta Therapeutics, LLC | $15.31 | 2022 | |
| Hartmann USA, INC. | $14.22 | 2022 | |
| Nevro Corp. | $13.30 | 2023 | Senza |
| Kerecis Limited | $13.04 | 2022 | |
| Grt US Holding, INC. | $7.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Recko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.